Silicon Republic
One to Watch series: new cancer therapy start-up TriMod Therapeutics (Video)

TriMod profiled in Enterprise Ireland's Technology Ireland Magazine
(page 20).

The Daily Business Post HPSU Startup of the Day: TriMod Therapeutics.

Radio interview on FocusSME Ireland: The Business Resource Dedicated to SMEs

Marshall et al; Cancer Res. 2012 Feb 1;72(3):581-91. Epub 2011 Dec 9.
Immunotherapy with PI3K Inhibitor and Toll-Like Receptor Agonist Induces IFN-γ+IL-17+ Polyfunctional T Cells That Mediate Rejection of Murine Tumors.

Conroy et al; Cancer Immunol Immunother. 2012 Mar;61(3):425-31. Epub 2011 Dec 23.
Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells.

Byrne et al; Cancer Res. 2011 Nov 15;71(22):6915-20. Epub 2011 Nov 8.
Targeting regulatory T cells in cancer (Review).

Toomey et al; Vaccine. 2008 Jun 25;26(27-28):3540-9.
Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma.

Jarnicki et al, J Immunol. 2008 Mar 15;180(6):3797-806.
Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics.

Conroy et al: Oncogene. 2008 Jan 7;27(2):168-80.
TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.

Jarnicki et al; J Immunol. 2006 Jul 15;177(2):896-904.
Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.